iVoice, Inc. Announces Patent Application Filing on Methodology for Talking Prescription Bottle with Voice Instructions via Wireless Technology
***
Business Editors MATAWAN, N.J.--(BUSINESS WIRE)--IVOC-- iVoice, Inc. (OTC Bulletin Board: IVOC), a leader in speech recognition technology, announced today it has filed an additional patent application with the U.S. Patent and Trademark Office. The application is titled: Methodology for Talking Prescription Bottle With Voice Instructions via Wireless Technology. Approximately three billion prescriptions are filled each year with the number of prescriptions expected to climb to four billion in 2004. Pharmacies have been struggling with the issue of label readability and comprehension for many years. With the iVoice patent pending technology, prescription bottles will tell users what medication is inside and the proper dosage, along with any other important directions and warnings. The present inventions include methods of communicating prescription instructions to the patient's medicine or prescription bottle. The methodology involves providing a medicine or prescription container with dosage instructions and warnings for the medication, via wireless technology. Optional software permits simultaneous labeling and wireless wav file transmission to make the medicine container a speaking product that is compliant with law. iVoice's commitment to innovative technology continues to help customers meet their client requirements. We believe that our intellectual property and our technology provide iVoice with a superior suite of application offerings designed for the Speech Recognition industry. About iVoice, Inc. iVoice, Inc. designs, manufactures and markets innovative voice and computer telephony communications systems for businesses and corporate departments. Its speech-enabled communication systems and software are designed to be cost effective solutions that improve a users calling experience by streamlining the call handling process through speech recognition technology. iVoice has demonstrated and met interoperability standards for many of the world's top telephony equipment manufacturers'. NOTE: Any statements that are not historical facts contained in this release are forward-looking statements. It is possible that the assumptions made by management for purposes of such statements may not materialize. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements may involve risks and uncertainties, including but not limited to those relating to product demand, pricing, market acceptance, the effect of economic conditions, and intellectual property rights, and the outcome of competitive products, risks in product development, the results of financing effort, the ability to complete transactions, and other risks identified in this release, and the Company's Securities and Exchange Commission filings. KEYWORD: NEW JERSEY INDUSTRY KEYWORD: PHARMACEUTICAL TELECOMMUNICATIONS SOFTWARE NETWORKING PRODUCT SOURCE: iVoice, Inc. CONTACT INFORMATION: iVoice, Inc. Investor Relations: Dolores Serafin 1-732-441-7700 and say "Investor Relations" investors@ivoice.com www.ivoice.com
posted
crap. i almost picked some it up this morning cause i thought something would happen with it soon.
Posts: 246 | Registered: Jan 2004
| IP: Logged |
posted
Ddog - can you clarify on why you said "some people don't like it (IVOC)"? Just curious - charts and fundamentals look pretty good to me.
Posts: 274 | Registered: Jan 2004
| IP: Logged |
posted
I am ridin' this one waiting for results as well I don't feel even the slightest bit nervous with this one I fully expect to see .007 very soon with no less than .0049
Posts: 412 | From: Tucson, AZ USA | Registered: Dec 2003
| IP: Logged |
iVoice, Inc. Announces New Record Date for the Distribution of Common Stock of Trey Resources, Inc. via COMTEX
February 4, 2004
MATAWAN, N.J., Feb 4, 2004 (BUSINESS WIRE) --
iVoice, Inc. (OTC Bulletin Board: IVOC), a provider of Speech Enabled applications, today announced that Trey Resources, Inc., its wholly-owned subsidiary engaged in the development of automatic appointment reminder technology, has filed with the Securities and Exchange Commission an amendment to its registration statement on Form SB-2. The amendment to the registration statement relates to the distribution by dividend to all of the stockholders of iVoice, Inc. as of February 9, 2004 of up to 3,000,000 shares of Trey Resources, Inc. Class A Common Stock.
The distribution will be made if and when SEC review of the proposed transaction has been completed and the registration statement is declared effective.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A preliminary prospectus relating to the securities may be obtained at the following link: http://www.sec.gov/Archives/edgar/data/1236275/000119380503000951 /0001193805-03-000951.txt
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field.)
About iVoice, Inc.
iVoice, Inc. designs, manufactures and markets innovative voice and computer telephony communications systems for businesses and corporate departments. Its speech-enabled communication systems and software are designed to be cost effective solutions that improve a users calling experience by streamlining the call handling process through speech recognition technology. iVoice has demonstrated and met interoperability standards for many of the world's top telephony equipment manufacturers'.
NOTE: Any statements that are not historical facts contained in this release are forward-looking statements. It is possible that the assumptions made by management for purposes of such statements may not materialize. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements may involve risks and uncertainties, including but not limited to those relating to product demand, pricing, market acceptance, the effect of economic conditions, and intellectual property rights, and the outcome of competitive products, risks in product development, the results of financing effort, the ability to complete transactions, and other risks identified in this release, and the Securities and Exchange Commission filings of iVoice, Inc.
SOURCE: iVoice, Inc.
iVoice, Inc. Investor Relations: Dolores Serafin 1-732-441-7700 and say 'Investor Relations' investors@ivoice.com www.ivoice.com
Health/Medical Writers / High-Tech Writers / Business Editors
DALLAS--(BUSINESS WIRE)--IPVO--
Addition of $3 Million in Sales Builds toward Corporate Expectation of $15 Million Annual Run Rate by End of First Quarter 2004
IPVoice Communications, Inc. (OTCBB:IPVO)(www.ipvoice.com) announced today completing the acquisition of a 51% equity interest in Medical Office Software, Inc. (MOS). MOS currently has $3 million in annual sales providing medical industry specific software and technology solutions to 3000 medical professional clients throughout South Florida. The acquisition is a benchmark event representing the Company's ability to execute on long-term plans. The IPVoice entry into Healthcare Communication Technology stems from a plan initiated eighteen months ago. IPVoice and MOS will immediately begin marketing Voice over Internet Protocol (VoIP) service and other services to the existing MOS customer list. Overall, IPVO will focus on delivering a complete portfolio of Internet Protocol (IP) communication solutions to assist medical professionals in meeting government mandated Health Care Industry Portability Act (HIPAA) requirements. "Adding MOS to IPVO's rapidly growing portfolio of companies and technology properties is an integral part of building revenues that are accretive to earnings," said Philip Verges, CEO of IPVoice. "Entering the Healthcare industry with an 18-year veteran company like MOS will accelerate both our sales, VoIP services, and our ability to deliver an overall portfolio of healthcare communication technologies that facilitate HIPAA compliance. We look forward to identifying other synergistic acquisition candidates as we continue to develop a company with a bottom-line, as well as a top-line, focus."
About Medical Office Software (www.mosonline.com)
MOS is an eighteen-year-old corporation providing medical industry software solutions to more than 3000 Physicians primarily in the South Florida Region. The Company's flagship Administrator product is a Medical Practice Management Software Package that includes billing, accounting and electronic claims filing.
About IPVoice Communications, Inc.
IPVoice is a six-year-old company that has reported as a research and development concern for most of its history. In 2002, IPVoice launched a new business plan, which has resulted in the Company posting five consecutive profitable quarters and establishing an annualized $10 million in revenue. The Company is actively acquiring early-stage proprietary technology companies and financially distressed systems integration companies in specific global markets. In 2003, IPVoice acquired Infotel Technologies in Singapore and IP Global Voice, led by CEO Peter Geddis, a former Executive Vice President and Chief Operating Officer of Qwest Communications (NYSE:Q) IPVoice plans to acquire additional companies similar to Infotel and IP Global Voice. This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to the risks inherent in the integration of Infotel Technologies into IPVoice Communications, Inc business, the ability of IPVoice to restore and stabilize the client base of Infotel and re-establish relationships with key suppliers, the development and market acceptance of the products and services of the combined companies, demand for the telecommunication and other products and related services, domestic and foreign government spending, budgetary and trade policies, economic and political changes in the domestic and international markets where the Company competes, successful deployment of advanced technologies, competitive product and pricing pressures as well as other risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.
KEYWORD: TEXAS FLORIDA INDUSTRY KEYWORD: MEDICAL TELECOMMUNICATIONS SOFTWARE E-COMMERCE INTERNET MERGERS/ACQ SOURCE: IPVoice Communications, Inc.
posted
SAME TRADER HAS BEEN ON THIS FOR THE LAST 47 MINUTES. BUYIN AND SELLIN BUYIN AND SELLIN. I KNOW CAUSE THE TIME IS EXACTLY THE SAME FOR THE LAST 132 TRADES. BOSS MUST BE ON HIM LIKE A WET BLANKET
As filed with the Securities and Exchange Commission on February 4, 2004 Registration No. 333-111695 ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 --------- iVoice, Inc. (Name of Registrant in Our Charter) New Jersey 7373 51-0471976 (State or Other Jurisdiction (Primary Standard (I.R.S. Employer of Incorporation Industrial Identification No.) or Organization) Classification Code Number) 750 Highway 34 Matawan, New Jersey 07747 (732) 441-7700 (Address and Telephone Number of Principal Executive Offices and Principal Place of Business) Jerome R. Mahoney 750 Highway 34 Matawan, New Jersey 07747 (732) 441-7700 (Name, address and telephone number of agent for service) Copies of all communications to: Scott S. Rosenblum, Esq. Lawrence A. Muenz, Esq. Kramer Levin Naftalis & Frankel LLP Meritz & Muenz, LLP 919 Third Avenue Three Hughes Place New York, New York 10022 Dix Hills, New York 11746 (212) 715-9100 (631) 242-7384 Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. |X| If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. |_| If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. |_| If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. |_| CALCULATION OF REGISTRATION FEE ======================================================================================= Proposed Maximum Proposed Offering Maximum Price Aggregate Amount Of Title Of Each Class Of Amount To Be Per Share Offering Registration Securities To Be Registered Registered(1) (2) Price (2) Fee (2) --------------------------------------------------------------------------------------- Class A common stock, no par value per share 4,700,000,000 $.00285 $13,395,000 $1,083.66 --------------------------------------------------------------------------------------- TOTAL 4,700,000,000 $.00285 $13,395,000 $1,083.66 ======================================================================================= (1) These shares consist of (i) 3,693,939,394 shares issuable pursuant to the terms of a standby equity distribution agreement dated December 31, 2003 between iVoice, Inc. and a certain investor, (ii) 306,060,606 shares issued to such investor and two other investors in connection with such agreement, and (iii) 700,000,000 issuable upon conversion of certain shares of our Class B common stock held by another investor. (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933. For the purposes of this table, we have used the average of the closing bid and asked prices as of December 30, 2003. (3) The registration fee was submitted on January 2, 2004 with the original filing of this registration statement. The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. Subject to completion, dated February 4, 2004 iVOICE, INC. 4,700,000,000 Shares of Class A Common Stock This prospectus relates to the sale of up to 4,700,000,000 shares of Class A common stock of iVoice, Inc. by the selling stockholders named in this prospectus. Please refer to "Selling Stockholders" beginning on page 10. We are not selling any shares of Class A common stock and, therefore, will not receive any proceeds from the sale of shares of Class A common stock by the selling stockholders. We will, however, receive proceeds from the sale of shares of our Class A common stock under a standby equity distribution agreement, referred to herein as the "Equity Distribution Agreement," entered into with Cornell Capital Partners, L.P. on December 31, 2003. Our shares of Class A common stock are traded on the Over-the-Counter Bulletin Board under the symbol "IVOC." On January 30, 2004, the last reported sale price of our Class A common stock was $ .0053 per share. Nevertheless, the prices at which the selling stockholders may sell the shares offered hereby will be determined by the prevailing market price for the shares or in negotiated transactions. The selling stockholders are: o Cornell Capital Partners, which intends to sell up to 3,993,939,394 shares of our Class A common stock. o CapStone Investments, which intends to sell up to 3,030,303 shares of our Class A common stock. o Butler Gonzalez LLP, which intends to sell up to 3,030,303 shares of our Class A common stock. o Jerome R. Mahoney, our president, chief executive officer and chief financial officer, who intends to sell up to 700,000,000 shares of our Class A common stock. Cornell Capital Partners is an "underwriter," within the meaning of the Securities Act of 1933, in connection with its sale of shares of our Class A common stock it receives under the Equity Distribution Agreement. On the date of each advance under the Equity Distribution Agreement, we will issue to Cornell Capital Partners shares of Class A common stock at a per share purchase price equal to the lowest closing bid price of our Class A common stock on the Over-the-Counter Bulletin Board during the five consecutive trading day period immediately following our request for such advance, subject to the provisions of the Equity Distribution Agreement. Pursuant to the Equity Distribution Agreement, we (i) agreed to pay to Cornell Capital Partners a cash fee equal to 5.5% of the amount of each advance and (ii) issued to Cornell Capital Partners 300,000,000 shares of our Class A common stock as a one-time commitment fee. The 5.5% cash fee and the one-time commitment fee are underwriting discounts. We engaged CapStone Investments, a registered broker-dealer, to act as placement agent in connection with the Equity Distribution Agreement. As payment for its placement agent services, we issued CapStone Investments an aggregate of 3,030,303 shares of Class A common stock. Investing in these securities is speculative and involves a high degree of risk. Please refer to "Risk Factors" beginning on page 4. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES, OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
posted
I'm still fuzzy on the impact of these types of PR (form filings, etc.) - are they generally good or bad for the stock?
Posts: 274 | Registered: Jan 2004
| IP: Logged |
posted
Ask price is now .0049 for anyone looking to get in on this below .005. I've just averaged down myself... confident this one has no where to go but UP from here.
Posts: 274 | Registered: Jan 2004
| IP: Logged |
posted
I've noticed IVOC has been aplying for and getting several patents over the past few months. Does anyone think this could be a good long term play, or just good for playing the bounces over the short term?
posted
I have actually felt that IVOC was a good long term. A few years back the stock traded at $6. Since I started trading last August, I've made some good money on it. My original buy in was at .0007. Within a couple months it went to as high as .017 one happy afternoon. If truly interested, there is a lot of DD available on this stock if you just hit search, top right on this site, and type in IVOC. They are partnered with some good companies, and I have always felt that it's not so much the company itself that would be worth money in the long run, but a possible buy out for all of the seemingly great patents they hold. Do Da Due people.
posted
iVoice, Inc. Announces Additional Information Regarding Recent Patent Application Filing
February 09, 2004 08:30:00 (ET)
MATAWAN, N.J., Feb 9, 2004 (BUSINESS WIRE) -- iVoice, Inc. (OTC Bulletin Board: IVOC), a leader in speech recognition technology, has released some additional comments and information in response to numerous inquiries regarding its recent filing of an additional patent application with the U.S. Patent and Trademark Office.
Jerry Mahoney, C.E.O. of iVoice, Inc. said, "The basic usage under the new patent application will allow pharmacists to simply take a medication bottle and wave or run it by a designated PC. That PC, via wireless technology, will automatically download the appropriate talking prescription instructions to the pill bottle. This information comes from either what the pharmacist has typed into the computer, via text to speech, or from an existing database of instructions for the prescribed medication prepared by the pharmaceutical manufacturer. When a person cannot read or understand the label on a medication bottle, errors in use can occur. The resulting errors can range from unfavorable reactions that are simply uncomfortable to untimely death. In particular, the elderly and people with visual and other disabilities have faced serious medical emergencies because they were unable to read the labels or instructions on their medications. When it's time to take the prescription, the patient simply presses a built-in button on the medication bottle to hear the message and instructions. In addition, the message prepared by the pharmaceutical manufacturer could contain additional information, including advertisements, additional information regarding the condition being treated, or any other message the company wishes to include to allow the company to establish further goodwill and branding relating to its products."
Mr. Mahoney added, "We feel that our patent application, 'Methodology for Talking Prescription Bottle with Voice Instructions via Wireless Technology' will become the preferred worldwide standard for delivering prescription instructions and medication warnings to consumers. iVoice is excited about expanding the use and applications relating to speech technology."
About iVoice, Inc.
iVoice, Inc. designs, manufactures and markets innovative voice and computer telephony communications systems for businesses and corporate departments. Its speech-enabled communication systems and software are designed to be cost effective solutions that improve a users calling experience by streamlining the call handling process through speech recognition technology. iVoice has demonstrated and met interoperability standards for many of the world's top telephony equipment manufacturers'.
NOTE: Any statements that are not historical facts contained in this release are forward-looking statements. It is possible that the assumptions made by management for purposes of such statements may not materialize. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements may involve risks and uncertainties, including but not limited to those relating to product demand, pricing, market acceptance, the effect of economic conditions, and intellectual property rights, and the outcome of competitive products, risks in product development, the results of financing effort, the ability to complete transactions, and other risks identified in this release, and the Company's Securities and Exchange Commission filings.
SOURCE: iVoice, Inc.
iVoice, Inc. Dolores Serafin 732-441-7700 and say "Investor Relations" investors@ivoice.com www.ivoice.com
Customize your Business Wire news & multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.